A Study of TransCon TLR7/8 Agonist With or Without Pembrolizumab in Patients With Advanced or Metastatic Solid Tumors
Public ClinicalTrials.gov record NCT04799054. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
Phase 1/2, Open-label, Dose Escalation and Dose Expansion Study of TransCon TLR7/8 Agonist Alone or in Combination With Pembrolizumab in Participants With Locally Advanced or Metastatic Solid Tumor Malignancies
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
TransCon TLR7/8 Agonist is an investigational drug being developed for treatment of locally advanced or metastatic solid tumors. This Phase 1/2 study will evaluate TransCon TLR7/8 Agonist as monotherapy or in combination with pembrolizumab in dose escalation and dose expansion. Participants will receive intratumoral (IT) injection of TransCon TLR7/8 Agonist every cycle. The primary objectives are to evaluate safety and tolerability, and define the Maximum Tolerated Dose (MTD) and Recommended Phase 2 Dose (RP2D) of TransCon TLR7/8 Agonist alone or in combination with pembrolizumab.
Study identification
- NCT ID
- NCT04799054
- Recruitment status
- Terminated
- Study type
- Interventional
- Phase
- Phase 1, Phase 2
- Enrollment
- 188 participants
Conditions and interventions
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Mar 17, 2021
- Primary completion
- Dec 1, 2025
- Completion
- Dec 1, 2025
- Last update posted
- Apr 12, 2026
2021 – 2025
United States locations
- U.S. sites
- 17
- U.S. states
- 10
- U.S. cities
- 16
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Ascendis Pharma Investigational Site | Duarte | California | 91010 | — |
| Ascendis Investigational Site | Los Angeles | California | 90067 | — |
| Ascendis Investigational Site | Orange | California | 92868 | — |
| Ascendis Pharma Investigational Site | San Francisco | California | 94158 | — |
| Ascendis Investigational Site | Tampa | Florida | 33612 | — |
| Ascendis Pharma Investigational Site | Chicago | Illinois | 60637 | — |
| Ascendis Pharma Investigational Site | Iowa City | Iowa | 52242 | — |
| Ascendis Pharma Investigational Site | Louisville | Kentucky | 40202 | — |
| Ascendis Pharma Investigational Site | Canton | Ohio | 44718 | — |
| Ascendis Pharma Investigational Site | Cincinnati | Ohio | 45219 | — |
| Ascendis Pharma Investigational Site | Cleveland | Ohio | 44106 | — |
| Ascendis Pharma Investigational Site | Pittsburgh | Pennsylvania | 15232 | — |
| Ascendis Pharma Investigational Site | Knoxville | Tennessee | 37920 | — |
| Ascendis Investigational Site | Dallas | Texas | 75235 | — |
| Ascendis Investigational Site | Dallas | Texas | 75390 | — |
| Ascendis Investigational Site | Houston | Texas | 77030 | — |
| Ascendis Pharma Investigational Site | Fairfax | Virginia | 22031 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 32 non-U.S. sites.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT04799054, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Apr 12, 2026 · Synced Sep 14, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT04799054 live on ClinicalTrials.gov.